India Q2 2023 Deal Trends, What May Be In Store
Executive Summary
India’s healthcare and life sciences segment saw deals worth over $3bn in Q2 2023 turbocharged by private equity activity in the hospitals space and smaller biopharma acquisitions. Watch the APIs and brands space for heightened M&A action, say experts.
You may also be interested in...
What’s In Store For CROs, CDMOs – “Stay In Your Swim Lane”, Consolidation, Divestitures
Brian Scanlan, operating partner (life sciences), Edgewater Capital Partners, in an interview with Scrip, outlines where things may be headed in the CRO/CDMO segment amid big pharma streamlining efforts, “belt tightening” by emerging biopharma, down rounds and heightened geopolitical tension.
Glenmark Divests API Company, Setting Out On Distinct Journeys
Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”
Glenmark Divests API Company, Setting Out On Distinct Journeys
Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”